Search
Now showing items 21-30 of 34
Evaluation of selected dye compounds as inhibitors of monoamine oxidase
(North-West University (South-Africa), 2019)
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative diseases that significantly impact the quality of life of patients. The pathology of Parkinson’s disease is characterised by neuronal death of the ...
Evaluation of selected dye compounds as inhibitors of enzymes, relevant to neurological disorders
(North-West University (South-Africa), 2021)
Neurological disorders such as Alzheimer’s disease, Parkinson’s disease and schizophrenia are disorders that affect a large part of the population, especially the elderly. The cause of these disorders is still not completely ...
Synthesis, characterisation and properties of fulvic acid, derived from a carbohydrate
(North-West University (South-Africa), 2019)
Introduction: Human and animal health is constantly threatened by pathogenic microbes and the emergence of bacteria resistant to standard medicinal interventions has escalated the search for new and innovative pharmaceutical ...
Synthesis and evaluation of sesamol derivatives as inhibitors of monoamine oxidase
(2014)
Parkinson’s disease is an age-related neurodegenerative disorder. The major symptoms of Parkinson’s disease are closely linked to the pathology of the disease. The main pathology of Parkinson’s disease consists of the ...
The synthesis and evaluation of phthalimide analogues as inhibitors of monoamine oxidase B
(North-West University, 2011)
Parkinson’s disease (PD) is a multifactorial neurodegenerative disease believed to be caused by a number of factors. This has made the successful treatment of the disease very difficult, as the underlying cause of degeneration ...
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
(2015)
Parkinson’s disease is a bradykinetic disorder that is the result of the death of dopaminergic neurons in the basal ganglia of the brain. This, in turn, leads to the depletion of dopamine in the striatum, which is responsible ...
Novel sulfanyl– and sulfinylcaffeine analogues as inhibitors of monoamine oxidase
(North-West University, 2013)
Parkinson’s disease (PD) is a neurodegenerative disorder, which is progressive in nature and usually associated with the elderly. It is the second most common age-related neurodegenerative disorder after Alzheimer’s disease ...
Inhibition of monoamine oxidase by selected 8–[(phenylsulfanyl)methyl]caffeine derivatives
(North-West University, 2012)
Purpose: Monoamine oxidase (MAO) consists of two isoforms, namely MAO-A and MAO-B. Both these isoforms are involved in the oxidation of dopamine. In Parkinson’s disease (PD) therapy, the inhibition of the oxidation of ...
The synthesis and evaluation of phenoxymethylcaffeine analogues as inhibitors of monoamine oxidase
(North-West University, 2010)
Purpose: Monoamine oxidase (MAO) plays a key role in the treatment of Parkinson's disease (PD), since it is the major enzyme responsible for the catabolism of dopamine in the substantia nigra of the brain. Inhibition of ...
The synthesis and evaluation of (E)-styrylisatin analogues as inhibitors of monoamine oxidase B
(North-West University, 2008)
Monoamine oxidase B (MAO-B) inhibitors are currently clinically used in the symptomatic
treatment of Parkinson's disease (PO) and may also possess .neuroprotective activity. The
irreversible MAO-'B inhibitor, (R)-deprenyl, ...